Edwards Lifesciences Corporation $EW Shares Sold by Swedbank AB

Key Points

• Swedbank AB reduced its stake in Edwards Lifesciences Corporation by 16.8%, selling 95,157 shares to hold a total of 470,253 shares, valued at approximately $36.78 million.
• The company's stock has seen a slight decline of 0.2%, with a current trading price of $74.39 and a market capitalization of $43.67 billion.
• Recent analyst ratings for Edwards Lifesciences have been mostly positive, with several upgrades and a target price increase, reflecting a consensus average rating of "Moderate Buy".

Swedbank AB decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 16.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,253 shares of the medical research company's stock after selling 95,157 shares during the quarter. Swedbank AB owned 0.08% of Edwards Lifesciences worth $36,778,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $266,000. Bank Pictet & Cie Europe AG lifted its stake in Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares in the last quarter. Snowden Capital Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $204,000. State of Wyoming lifted its stake in Edwards Lifesciences by 128.2% in the 4th quarter. State of Wyoming now owns 1,935 shares of the medical research company's stock valued at $143,000 after buying an additional 1,087 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in Edwards Lifesciences by 67.7% in the 4th quarter. Two Sigma Investments LP now owns 125,032 shares of the medical research company's stock valued at $9,256,000 after buying an additional 50,463 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 1.6%

Shares of EW stock traded up $1.15 on Tuesday, reaching $74.90. 978,471 shares of the stock were exchanged, compared to its average volume of 4,467,467. The stock has a market cap of $43.97 billion, a P/E ratio of 10.77, a price-to-earnings-growth ratio of 3.59 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $78.59 and a two-hundred day moving average of $75.58. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the prior year, the company earned $0.70 EPS. The firm's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on EW shares. Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $86.61.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.